美第奇新星生物技術 MNOV 深 滬
等待開盤 09-25 09:30:00 美东时间
2.65
-0.150
-5.36%
華盛通- 最 高2.67
- 今 開2.67
- 成交量 45.23万股
- 最 低 2.4801
- 昨 收 2.80
- 總市值 1.30亿
- 52周最高 3.8999
- 市盈率 靜 --
- 換手率 0.92%
- 52周最低 1.168
- 委 比 -90.81%
- 總股本 4922.12万
- 歷史最高 14.50
- 量 比 0.18
- 振 幅 6.78%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label Extension phase. The LPLV for the entire study is expected in March 2027. MediciNova...
09-24 18:10
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.
09-17 17:52
MediciNova to Participate in Two Investor Conferences in September
<p>MediciNova, Inc. announced that its President and CEO, Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer, David H. Crean, Ph.D., will participate in two investor conferences in September. They will attend the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16 and the ROTH Capital 5th Annual Healthcare Opportunities Conference on September 29. Both events will feature virtual presentations and investor meetings. The...
09-08 10:00
MediciNova Ends Standby Equity Financing Agreement
The latest update is out from Medicinova ( ($MNOV) ). MediciNova, Inc. terminat...
09-02 19:58
MediciNova Updates Executive Contracts, Enhancing Change-in-Control Protection
Medicinova ( ($MNOV) ) just unveiled an update. On August 17, 2026, MediciNova ...
08-19 19:58
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova announced the successful enrollment of 200 patients in the NIH-funded SEANOBI-ALS study evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS). This milestone reflects strong community engagement and collaboration. The study provides MN-166 to ALS patients ineligible for other trials. Final follow-ups are expected in early 2027, with data analysis to follow. MN-166 is a PDE4 inhibitor and anti-inflammatory compound in la...
07-15 12:00
MediciNova 3000万美元资金支持赢得缓冲时间 如今投资者需要渐冻症相关数据而非空谈
MediciNova通过股权发售协议（SEPA）获得未来36个月内最高3000万美元的普通股融资额度，可按市价的97%向认购方发售股票，动用该额度会产生股权稀释...
06-30 20:29
MediciNova CEO Provides Shareholder Update
MediciNova, Inc. has made significant progress in its key programs, including the completion of the last patient last visit in its Phase 2 clinical trial of MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD associated with T2DM. The company also expanded its MN-166 (ibudilast) SEANOBI study for ALS, enrolling 100 patients, and received a U.S. patent allowance for ibudilast in combination with anti-PD-1 antibodies for glioblastoma. A...
06-30 12:00
MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma
Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad range of treatment
06-08 20:07
